Mandate

Vinge advises Industrifonden in connection with an investment in Cellevate

July 03, 2023 M&A

Vinge has advised Industrifonden in connection with its investment in Cellevate. Cellevate is an innovative biotech company that develops the next generation of cell culture systems.

Vinge’s team primarily consisted of Johan Larsson, Ellinor Wargenbrant and Stojan Arnerstål

Related

Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023